Epigenetics: Unwrapping the Future for Drug Discovery?

Bentley University
Waltham, MA 
Thursday, October 20, 2011 
8:00 am - 6:00 pm


8:00-9:00 am Check-in, Light breakfast, / Exhibitor setup
9:00-9:10 am Opening Remarks
Rajvi Chopra, Novartis
Session I Chair: Sharon Townson
9:10-9:55 am "Defining the Cancer Epigenome and its Potential for Therapeutic Targeting"
Stephen Baylin, The John Hopkins University - School of Medicine
9:55-10:30 am "Protein Methyltransferase Inhibitors as Personalized Cancer Therapeutics"
Robert Copeland, Epizyme
10:30-11:00 am Coffee
Session II Chair: Nessa Carey
11:00-11:35 am "The Intersection of Structural Biology and Epigenetics"
Steve Bellon, Constellation Pharmaceuticals
11:35-12:20 pm "Structural and chemical biology of readers and writers of the histone code"
Cheryl Arrowsmith, SGC - Toronto
12:20-1:10 pm Lunch
Session III Chair: Elizabeth Sprague
1:10-1:55 pm "Mechanisms for Coordinated DNA Methylation and Histone Methylation"
Xiaodong Cheng, Emory University School of Medicine
1:55-2:30 pm "Chemical Inhibition of Bromodomains"
James Bradner, Dana Farber Cancer Institute / HMS
2:30-3:00 pm Coffee
Session IV Chair: Steven Kazmirski
3:00-3:35 pm "Molecular recognition of nucleosomes by chromatin factors and enzymes"
Song Tan, Penn State University
3:35-4:10 pm "Structural Basis of Substrate Methylation and Inhibition of SMYD2"
Andrew Ferguson, AstraZeneca
4:10-4:45 pm "Epigenetic therapies in non-oncology indications - the opportunities and the challenges"
Nessa Carey, Pfizer UK
4:45 pm Mixer

Meeting Organizers:

Meeting Sponsors:

Back to top